SAB Biotherapeutics, Inc.

Direct answer

SAB Biotherapeutics, Inc. is publicly traded on NASDAQ under the ticker SABS.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical...

Can you invest in SAB Biotherapeutics, Inc.?

Yes. SAB Biotherapeutics, Inc. trades publicly on NASDAQ as SABS.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for SAB Biotherapeutics, Inc.

Detailed equity research is provided by MarketSnap.